Aurinia Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved its Lupkynis (voclosporin) treatment for use in adult patients with …
Shares in Aurinia Pharmaceuticals (AUPH) tanked 10% after-hours after the biopharma announced disappointing topline data from the Phase 2/3 Audrey clinical study evaluating …
Shares in Aurinia Pharma (AUPH) surged 9% in Tuesday’s extended trading after the U.S.
Shares in Aurinia Pharmaceuticals, Inc (AUPH) advanced in pre-market trading as the biotech company announced the submission of the New Drug Application (NDA) …
Finding a stock which will deliver enormous returns is the Street’s holy grail. Upon first glance, this task may seem rather simple.
Cantor analyst Elemer Piros is out with a short research note on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH), following the company’s first-quarter financial results and update on …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) just scored what H.C.
Analysts offer insights into a volatile biotech-verse amid Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares dipping on news of a program termination and Aurinia Pharmaceuticals (NASDAQ:AUPH) soaring on …
Investors in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) should be smiling from ear to ear today after the company announced positive 24-week data in 10 patients from …